{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:07:33Z","timestamp":1774451253506,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01260-6","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:43:59Z","timestamp":1750985039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer"],"prefix":"10.1007","volume":"56","author":[{"given":"Karin","family":"Potthoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Marschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lerchenm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Depenbusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil","family":"Boller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Niemeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Zirrgiebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"1260_CR1","doi-asserted-by":"crossref","unstructured":"Duan B, Zhao Y, Bai J, Wang J, Duan X, Luo X, Zhang R, et al. Colorectal cancer: an overview. In: Morgado-Diaz JA, editor. Gastrointestinal cancers. Brisbane: Exon Publications; 2022. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK586003\/.\u00a0","DOI":"10.36255\/exon-publications-gastrointestinal-cancers-colorectal-cancer"},{"issue":"Suppl 3","key":"1260_CR2","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","volume":"25","author":"E Van Cutsem","year":"2014","unstructured":"Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(Suppl 3):iii1-9. https:\/\/doi.org\/10.1093\/annonc\/mdu260.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1260_CR3","doi-asserted-by":"publisher","first-page":"e000813","DOI":"10.1136\/esmoopen-2020-000813","volume":"4","author":"V De Falco","year":"2020","unstructured":"De Falco V, Napolitano S, Rosell\u00f3 S, et al. How we treat metastatic colorectal cancer. ESMO Open. 2020;4:e000813. https:\/\/doi.org\/10.1136\/esmoopen-2020-000813.","journal-title":"ESMO Open"},{"key":"1260_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer\u2014A GERCOR Study. J Clin Oncol. 2006;24:394\u2013400. https:\/\/doi.org\/10.1200\/JCO.2005.03.0106.","journal-title":"J Clin Oncol"},{"key":"1260_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer. J Clin Oncol. 2009;27:663\u201371. https:\/\/doi.org\/10.1200\/JCO.2008.20.8397.","journal-title":"J Clin Oncol"},{"key":"1260_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25:1346\u201355. https:\/\/doi.org\/10.1093\/annonc\/mdu141.","journal-title":"Ann Oncol"},{"key":"1260_CR7","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:1386\u2013422. https:\/\/doi.org\/10.1093\/annonc\/mdw235.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1260_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne C-H, Hitre E, et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. N Engl J Med. 2009;360:1408\u201317. https:\/\/doi.org\/10.1056\/NEJMoa0805019.","journal-title":"N Engl J Med"},{"key":"1260_CR9","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","volume":"22","author":"C Bokemeyer","year":"2011","unstructured":"Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2011;22:1535\u201346. https:\/\/doi.org\/10.1093\/annonc\/mdq632.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"1260_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4812","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Lenz H-J, Kohne C-H, et al. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. J Clin Oncol. 2015. https:\/\/doi.org\/10.1200\/JCO.2014.59.4812.","journal-title":"J Clin Oncol"},{"key":"1260_CR11","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"J-Y Douillard","year":"2010","unstructured":"Douillard J-Y, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:4697\u2013705. https:\/\/doi.org\/10.1200\/JCO.2009.27.4860.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1260_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00384-017-2800-1","volume":"32","author":"F Rivera","year":"2017","unstructured":"Rivera F, Karthaus M, Hecht JR, et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis. 2017;32:1179\u201390. https:\/\/doi.org\/10.1007\/s00384-017-2800-1.","journal-title":"Int J Colorectal Dis"},{"key":"1260_CR13","doi-asserted-by":"publisher","first-page":"15176","DOI":"10.1002\/cam4.6196","volume":"12","author":"Y-H Liang","year":"2023","unstructured":"Liang Y-H, Chen K-H, Shao Y-Y. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study. Cancer Med. 2023;12:15176\u201386. https:\/\/doi.org\/10.1002\/cam4.6196.","journal-title":"Cancer Med"},{"key":"1260_CR14","unstructured":"Marschner N, Uhlig J, Jacobasch L, et al. Prospective validation of the modified metastatic colon cancer score (mCCS) in >600 patients with RAS wildtype metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI\/FOLFOX: Final results of the non-interventional study VALIDATE. Prep"},{"key":"1260_CR15","doi-asserted-by":"publisher","first-page":"1246716","DOI":"10.3389\/fonc.2023.1246716","volume":"13","author":"S Cherri","year":"2023","unstructured":"Cherri S, Oneda E, Zanotti L, Zaniboni A. Optimizing the first-line treatment for metastatic colorectal cancer. Front Oncol. 2023;13:1246716. https:\/\/doi.org\/10.3389\/fonc.2023.1246716.","journal-title":"Front Oncol"},{"key":"1260_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1200\/JCO.21.01332","volume":"40","author":"DP Modest","year":"2022","unstructured":"Modest DP, Karthaus M, Fruehauf S, et al. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). J Clin Oncol. 2022;40:72\u201382. https:\/\/doi.org\/10.1200\/JCO.21.01332.","journal-title":"J Clin Oncol"},{"key":"1260_CR17","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.2024.42.16_suppl.3506","volume":"42","author":"DP Modest","year":"2024","unstructured":"Modest DP, Karthaus M, Fruehauf S, et al. FU\/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses. J Clin Oncol. 2024;42:3506\u20133506. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3506.","journal-title":"J Clin Oncol"},{"key":"1260_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.annonc.2019.10.007","volume":"31","author":"E Martinelli","year":"2020","unstructured":"Martinelli E, Ciardiello D, Martini G, et al. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:30\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.007.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1260_CR19","doi-asserted-by":"publisher","first-page":"104106","DOI":"10.1016\/j.critrevonc.2023.104106","volume":"191","author":"L Mastrantoni","year":"2023","unstructured":"Mastrantoni L, Beccia V, Caira G, et al. Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis. Crit Rev Oncol Hematol. 2023;191:104106. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104106.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1260_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ejca.2018.06.024","volume":"101","author":"E Aranda","year":"2018","unstructured":"Aranda E, Garc\u00eda-Alfonso P, Benavides M, et al. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as\u00a0maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD\u00a0study. Eur J Cancer Oxf Engl 1990. 2018;101:263\u201372. https:\/\/doi.org\/10.1016\/j.ejca.2018.06.024.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"1260_CR21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","volume":"16","author":"S Hegewisch-Becker","year":"2015","unstructured":"Hegewisch-Becker S, Graeven U, Lerchenm\u00fcller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015;16:1355\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(15)00042-X.","journal-title":"Lancet Oncol"},{"key":"1260_CR22","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","volume":"385","author":"LHJ Simkens","year":"2015","unstructured":"Simkens LHJ, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet Lond Engl. 2015;385:1843\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(14)62004-3.","journal-title":"Lancet Lond Engl"},{"key":"1260_CR23","doi-asserted-by":"publisher","first-page":"e194489","DOI":"10.1001\/jamaoncol.2019.4489","volume":"6","author":"MB Sonbol","year":"2020","unstructured":"Sonbol MB, Mountjoy LJ, Firwana B, et al. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol. 2020;6:e194489. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4489.","journal-title":"JAMA Oncol"},{"key":"1260_CR24","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","volume":"5","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Morano F, Corallo S, et al. Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5:1268\u201375. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1467.","journal-title":"JAMA Oncol"},{"key":"1260_CR25","doi-asserted-by":"publisher","first-page":"e2333533","DOI":"10.1001\/jamanetworkopen.2023.33533","volume":"6","author":"V Boige","year":"2023","unstructured":"Boige V, Blons H, Fran\u00e7ois E, et al. Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer. JAMA Netw Open. 2023;6:e2333533. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.33533.","journal-title":"JAMA Netw Open"},{"key":"1260_CR26","doi-asserted-by":"publisher","first-page":"e78709","DOI":"10.1371\/journal.pone.0078709","volume":"8","author":"Y-C Lee","year":"2013","unstructured":"Lee Y-C, Lee Y-L, Chuang J-P, Lee J-C. Differences in Survival between Colon and Rectal Cancer from SEER Data. PLoS ONE. 2013;8:e78709. https:\/\/doi.org\/10.1371\/journal.pone.0078709.","journal-title":"PLoS ONE"},{"key":"1260_CR27","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"J-Y Douillard","year":"2013","unstructured":"Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1305275.","journal-title":"N Engl J Med"},{"key":"1260_CR28","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, K\u00f6hne C-H, L\u00e1ng I, et al. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J Clin Oncol. 2011;29:2011\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.33.5091.","journal-title":"J Clin Oncol"},{"key":"1260_CR29","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1158\/1078-0432.CCR-14-2313","volume":"21","author":"SM Cushman","year":"2015","unstructured":"Cushman SM, Jiang C, Hatch AJ, et al. Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance). Clin Cancer Res. 2015;21:1078\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2313.","journal-title":"Clin Cancer Res"},{"key":"1260_CR30","doi-asserted-by":"publisher","first-page":"e000353","DOI":"10.1136\/esmoopen-2018-000353","volume":"3","author":"RM Goldberg","year":"2018","unstructured":"Goldberg RM, Montagut C, Wainberg ZA, et al. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open. 2018;3:e000353. https:\/\/doi.org\/10.1136\/esmoopen-2018-000353.","journal-title":"ESMO Open"},{"key":"1260_CR31","doi-asserted-by":"publisher","first-page":"53631","DOI":"10.18632\/oncotarget.19022","volume":"8","author":"D-D Cao","year":"2017","unstructured":"Cao D-D, Xu H-L, Xu X-M, Ge W. The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis. Oncotarget. 2017;8:53631\u201341. https:\/\/doi.org\/10.18632\/oncotarget.19022.","journal-title":"Oncotarget"},{"key":"1260_CR32","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2017.35.15_suppl.3503","volume":"35","author":"AP Venook","year":"2017","unstructured":"Venook AP, Ou F-S, Lenz H-J, et al. Primary (1\u00b0) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB \/ SWOG 80405 (Alliance). J Clin Oncol. 2017;35:3503\u20133503. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.3503.","journal-title":"J Clin Oncol"},{"key":"1260_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1470-2045(14)70106-8","volume":"15","author":"H Wasan","year":"2014","unstructured":"Wasan H, Meade AM, Adams R, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with< i> KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014;15:631\u20139.","journal-title":"Lancet Oncol"},{"key":"1260_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2023;34:10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01260-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:04:24Z","timestamp":1751029464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01260-6","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"14 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests\u00a0concerning the topic of this publication. Outside of the published work, the institutions of LM, SS, CL, RD and HT received remuneration for the documentation of patient data; NM declares stock ownership and upper management responsibility (iOMEDICO); SS declares stock ownership (Merck); HT declares stock ownership (CHOP GmbH, VISION MED GmbH, Care and Coach GmbH).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}